erenumab
Sign in to saveAlso known as AMG334, Aimovig
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
Key facts
- Drug.type
- mab
- Drug.image
- File:Aimovig Autoinjector.jpg
- Drug.alt
- A standard 70mg/mL Aimovig autoinjector
- Drug.caption
- A standard 70mg/mL Aimovig autoinjector
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- CGRPR
- Drug.tradename
- Aimovig
- Drug.MedlinePlus
- a618029
- Drug.DailyMedID
- Erenumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous injection
- Drug.ATC_prefix
- N02
- Drug.ATC_suffix
- CD01
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
759 papers- Erenumab.2006
- Erenumab for episodic migraine.Pain management · 2022
- A Controlled Trial of Erenumab for Episodic Migraine.The New England journal of medicine · 2017
- Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.Cephalalgia : an international journal of headache · 2022
- Erenumab.2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 145871.98
- Has use
- medication
Show 4 more facts
- medical condition treated
- migraine
- World Health Organisation international non-proprietary name
- erenumab
- chemical formula
- C₆₄₇₂H₉₉₆₄N₁₇₂₈O₂₀₁₈S₅₀
- subject has role
- calcitonin gene-related peptide receptor antagonist
via Wikidata · CC0
~3 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Economics
- Legal status
- Names
- References
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
Erenumab, which was developed by Amgen and Novartis, was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration. In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1million prescriptions.
Excerpted from Wikipedia’s “erenumab” article, available under the CC BY-SA 4.0 licence.